Ischemic-reperfused rat skeletal muscle: The effect of vasoactive intestinal peptide (VIP) on contractile force, oxygenation and antioxidant enzyme systems

被引:19
作者
Tuncel, N [1 ]
Erden, S [1 ]
Uzuner, K [1 ]
Altiokka, G [1 ]
Tuncel, M [1 ]
机构
[1] UNIV ANADOLU,FAC PHARM,DEPT ANALYT CHEM,TR-26480 ESKISEHIR,TURKEY
关键词
vasoactive intestinal peptide; ischemia-reperfusion skeletal muscle; antioxidant enzymes; rat;
D O I
10.1016/S0196-9781(96)00289-6
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The effect of vasoactive intestinal peptide (VIP) on the nerve-stimulated contraction, tissue oxygenation, lipid peroxidation and antioxidant enzymes activities-superoxide dismutase and catalase was investigated in the rat gastrocnemius muscle exposed to 4 h ischemia-4hr reperfusion. Ischemia caused significant decrease in muscle contractile force, oxygenation and superoxide dismutase enzyme activity. Reperfusion of ischemic muscle increased the muscle contractile force and restored the tissue oxygenation to the baseline lever. Superoxide dismutase and catalase activities of reperfused muscle increased significantly. However neither ischemia nor reperfusion affected gastrocnemius muscle malondialdehide (MDA) levels. VIP administration at the onset of reperfusion significantly increased skeletal muscle contractile force and tissue oxygenation even higher than baseline and reperfusion values. VIP also normalized the increased superoxide dismutase and catalase activities of reperfused skeletal muscle. In conclusion, VIP, acting as a powerful antioxidant and preserving contractile machinery seems to be a promising endogenous peptide that can salvage the skeletal muscle from severe ischemia-reperfusion injury. (C) 1997 Elsevier Science Inc.
引用
收藏
页码:269 / 275
页数:7
相关论文
共 42 条
[1]  
AKIN MZ, 1993, PHARMACOLOGY, V47, P194
[2]   EFFECT OF VASOACTIVE INTESTINAL PEPTIDE ON MYOCARDIAL-CONTRACTILITY AND CORONARY BLOOD-FLOW IN THE DOG - COMPARISON WITH ISOPROTERENOL AND FORSKOLIN [J].
ANDERSON, FL ;
KRALIOS, AC ;
HERSHBERGER, R ;
BRISTOW, MR .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1988, 12 (03) :365-371
[3]  
ASCER E, 1992, J CARDIOVASC SURG, V33, P588
[4]  
BASLER IK, 1994, VASOACTIVE INTESTINA, P433
[5]  
BELKIN M, 1988, Surgical Forum (Chicago), V39, P308
[6]   VASOACTIVE-INTESTINAL-PEPTIDE PREVENTS LUNG INJURY DUE TO XANTHINE XANTHINE-OXIDASE [J].
BERISHA, H ;
FODA, H ;
SAKAKIBARA, H ;
TROTZ, M ;
PAKBAZ, H ;
SAID, SI .
AMERICAN JOURNAL OF PHYSIOLOGY, 1990, 259 (02) :L151-L155
[7]   PROTECTION OF THE ISCHEMIC SKELETAL-MUSCLE [J].
BEYERSDORF, F .
THORACIC AND CARDIOVASCULAR SURGEON, 1991, 39 (01) :19-28
[8]   LEUKOCYTE ACTIVATION IN ISCHEMIA REPERFUSION INJURY OF SKELETAL-MUSCLE [J].
CAMBRIA, RA ;
ANDERSON, RJ ;
DIKDAN, G ;
TEEHAN, EP ;
HERNANDEZMALDONADO, JJ ;
HOBSON, RW .
JOURNAL OF SURGICAL RESEARCH, 1991, 51 (01) :13-17
[9]   DEFEROXAMINE PREVENTS LIPID-PEROXIDATION AND ATTENUATES REOXYGENATION INJURY IN POSTISCHEMIC SKELETAL-MUSCLE [J].
FANTINI, GA ;
YOSHIOKA, T .
AMERICAN JOURNAL OF PHYSIOLOGY, 1993, 264 (06) :H1953-H1959
[10]  
FAUST KB, 1988, AM SURGEON, V54, P709